Fate Therapeutics Inc (NAS:FATE)
$ 3.68 0.23 (6.67%) Market Cap: 418.90 Mil Enterprise Value: 111.25 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 58/100

Q1 2019 Fate Therapeutics Inc Earnings Call Transcript

May 07, 2019 / 09:00PM GMT
Release Date Price: $16.98 (-5.19%)
Operator

Welcome to the Fate Therapeutics First Quarter 2019 Financial Results Conference Call. (Operator Instructions) This call is being webcast live on Investors & Media section of Fate's website at fatetherapeutics.com. As a reminder, today's call is being recorded.

I would now like to introduce Scott Wolchko, President and Chief Executive Officer of Fate therapeutics. Please begin, sir.

J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, CFO, President, Treasurer, Secretary & Director

Thank you. Good afternoon and thanks everyone for joining us for the Fate Therapeutics first quarter 2019 financial results call. Shortly after 4:00 PM Eastern Time today, we issued a press release with these results, which can be found on the Investors & Media section of our website under Press Releases. In addition, our Form 10-Q for the quarter ended March 31, 2019, was filed shortly thereafter and can be found on the Investors & Media section of our website under, Financial Information.

Before we begin, I'd like to remind everyone that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot